[1] Castleman B, McNeely BU. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. case 22-1971 [J]. N Engl J Med, 1971,284(22): 1260-1266. [2] Danon AD, Krishnan J, Frizzera G. Morpho-immunophenotypic diversity of Castleman's disease, hyaline-vascular type: with emphasis on a stromarich variant and a new pathogenetic hypothesis [J]. Virchows Arch A Pathol Anat Histopathol, 1993, 423(5): 369-382. [3] El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics [J]. Oncologist, 2011, 16(4): 497-511. [4] Khan J, von Sinner W, Akhtar M, et al. Castleman's disease of the chest. magnetic resonance imaging features [J]. Chest, 1994,105(5):1608-1610. [5] McAdams HP, Rosado-de-Christenson M, Fishback NF, et al. Castleman disease of the thorax: radiologic features with clinical and histopathologic correlation [J]. Radiology, 1998, 209(1): 221-228. [6] Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations [J]. Cancer, 1972, 29(3): 670-683. [7] Racil H, Cheikh Rouhou S, Ismail O, et al. Castleman's disease: an intrapulmonary form with intrafissural development [J]. Scientific World J, 2009, 9: 940-945. [8] Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric castleman's disease: ANRS 117 CastlemaB Trial [J]. J Clin Oncol, 2007, 25(22): 3350-3356. |